Search
Menu
Home
HTB
2010
August
26
26 August 2010
Contents
Editorial
Volume 11 Number 7/8 July/August2010
Conference reports
XVIII International AIDS Conference: 18-23 July 2010, Vienna
Navigating the IAS Vienna conference online
Results from the Caprisa 004 tenofovir microbicide trial
Quadrivalent HPV vaccine reduces genital lesions and HPV acquisition in men
Rilpivirine (TMC-278) vs efavirenz in treatment-naive patients: phase 3 results
Once-daily nevirapine extended release (XR) is non-inferior to current formulation
GSK572 (dolutegravir): second-generation integrase inhibitor
TBR-652: early results for CCR5 inhibitor
Atazanavir/r plus maraviroc or tenofovir/FTC in treatment-naive patients
Unboosted twice-daily atazanavir plus raltegravir
CASCADE analysis of when to start treatment
Impact of antiretroviral PMTCT prophylaxis regimens on subsequent maternal disease progression in Kesho Bora
Birth outcomes with antiretroviral exposure
New WHO guidelines for children (July 2010)
Early treatment for infants is cost-effective
No difference in outcomes for children initiating treatment with a protease inhibitor or an NNRTI nor with viral load switching strategies in PENPACT-1
Tablets more acceptable than syrups in the ARROW trial
Paediatric formulation of TMC 278
Smoking and atazanavir levels
Darunavir/ritonavir and rosuvastatin
Lime juice is not a microbicide: do not try at home
Antiretrovirals
FDA safety updates to antiretroviral labels
Raltegravir approved inScotland
Atazanavir/r approved in Europefor children aged 6 to 18 years
FDA finally approves 4th generation HIV Ag/Ab test in the US
Treatment access
FDA approval of generic ARVs
Pregnancy
Potential impact of new WHO pregnancy guidance (2010)
Access to formula milk for HIV-positive mothers in the UK
PK and drug interactions
Darunavir/ritonavir and hepatic impairment
Case report lack of PK interaction between bosentan and nevirapine
Pharmacokinetics of once daily darunavir/ritonavir and efavirenz
Basic science and immunology
HIV infection, inflammation and premature ageing
Antiretroviral therapy dramatically reduces HIV transmission
On the web
Conference reports and online abstracts
Reports and journals
Community resources and publications
Medical resources
HTB RSS
Early access
HIV organisations support trans and non-binary communities against the unworkable EHRC guidelines
30 June 2025
Long-acting injectable PrEP approved in the US: priced at $28,000 a year
28 June 2025
Clinical studies of two once-weekly pipeline compounds put on hold
27 June 2025
UK HIV care for transgender and non-binary people: comment on unworkable EHRC guidelines by 30 June
26 June 2025
All early access reports
Current issues
June 2025
May 2025
April 2025
Back issues
Special report
UK HIV care for transgender and non-binary people: comment on unworkable EHRC guidelines by 30 June
26 June 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate